HTG Appoints TJ Johnson President and CEO

TUCSON, Ariz.--(Business Wire)--HTG, Inc., a provider of novel array-based gene expression assay
technology and services for the life sciences industry, today
announced that it has appointed Tim (TJ) Johnson to the position of
president and chief executive officer. Johnson, a seasoned and
accomplished management executive, joins HTG from LVC Consulting where
he was a partner with the firm. Previously, he was senior vice
president of global business services at Ventana Medical Systems, a
leading provider of diagnostic solutions for anatomical pathology.

"We are very pleased that TJ has joined us at HTG at this
important juncture for the company," said Harry George, chairman of
HTG and managing partner, Solstice Capital. "His senior management and
operational experience at Ventana, as it grew from $70 million when he
joined the company to nearly $300 million, will help HTG reach the
full commercial potential of its breakthrough tools for drug discovery
and diagnostics."

"HTG affords me a terrific opportunity to apply my experience to
strengthen the organization, accelerate growth and drive adoption of
the company's innovative technology platform," said Johnson.

Johnson spent five years with Ventana Medical Systems in various
senior management positions of increasing responsibility. Prior to
Ventana Medical Systems, Johnson was vice president of global
marketing at Hillenbrand Industries where he served as general manager
of an acquisition company and handled North American operations in
addition to leading the global strategic planning team. He has also
served as a senior consulting manager at Price Waterhouse and has
sales and operational experience at Batesville Casket Company, Caloric
Corporation and Frito-Lay.

Johnson earned a B.S. in business from Indiana University.

HTG's qNPA technology is used to carry out quantitative
multiplexed, gene-based drug discovery programs, including target
validation, HTS lead optimization, metabolism, toxicology and clinical
development. HTG's platform allows scientists to test any sample,
including fixed tissues, while avoiding the need for extraction or
target amplification. The platform provides high-quality quantitative
test results enabling clients to compress drug discovery and
development program timelines, increase program success and reduce
costs.

About HTG

Privately-held HTG is based in Tucson, Arizona. Investors in the
company include Solstice Capital, Valley Ventures, Merck Capital
Ventures, Village Ventures and Arcturus Capital. Additional
information is available at www.htgenomics.com.

Schwartz Communications, Inc.
Risa Burgess, 781-684-0770
htg@schwartz-pr.com

Copyright Business Wire 2008